Published in final edited form as:

Tetrahedron Lett. 2007 June 18; 48(25): 4339–4342.

Enantioselective synthesis of α -aminopropargylphosphonates

Rajasekhar Dodda and Cong-Gui Zhao*

Department of Chemistry, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas 78249-0698

Abstract

α -Aminopropargylphosphonates have been synthesized for the first time in good yields and enantiomeric excesses (up to 81% ee) by using a copper(I)-pybox complex as the catalyst.

Keywords

aminopropargylphosphonate; alkyne; iminophosphonate; copper(I) triflate; pybox; enantioselective; phosphonate

α -Aminophosphonic acids, as structural mimics of α -amino acids, exhibit a broad spectrum of biological activities.^{1–3} These compounds have already been found to act as antibacterial agents, neuroactive compounds, anticancer drugs, and pesticides, with some of them already commercialized.^{1–3} As is the case of α -amino acids, the absolute configuration of the amino-substituted α -carbon of α -aminophosphonic acids have significant influence on the observed biological activities.² Consequently, the asymmetric synthesis of α -aminophosphonates has been the focus of recent research.⁴ Besides the enzymatic resolution of racemic α -aminophosphonates,³ several chemical methods^{1,4} have been reported for the synthesis of enantioenriched α -aminophosphonates, either diastereoselectively or enantioselectively. Among the reported chemical methods, Mannich-type addition of phosphorus nucleophiles to imines (i.e., C-P bond formation) represents one of the most useful methods for obtaining enantioenriched α -aminophosphonates.⁵ Alternatively, optically active α -aminophosphonates may be obtained through the addition of carbon nucleophiles to iminophosphonates (i.e., C-C bond formation),^{6,7} as exemplified by the recent elegant work from the Kobayashi group.⁷ Nonetheless, this synthetic pathway has not been fully explored.

Synthesis of propargylamines from imines through the direct addition of terminal alkynes by using metal complexes is well known in the literature.⁸ Because of our continued interests in the synthesis of enantioenriched α -substituted phosphonate derivatives,⁹ recently we extended this reaction to α -iminophosphonates and developed the first general synthesis of α -aminopropargylphosphonates by using silver(I) or copper(I) salts as the catalysts.¹⁰ These results represent another example of carbon-carbon bond formation for the synthesis of α -aminophosphonates. Because the alkynyl triple bond may be readily elaborated to induce other functional groups, the products of this novel reaction, α -aminopropargylphosphonates, should be versatile substrates for the synthesis of other α -aminophosphonate derivatives. Additionally, these compounds may possess interesting biological activities by themselves, although they have not been evaluated for this purpose in the past.

*Corresponding author. Tel.: +1-210-458-5432; fax: +1-210-458-7428; e-mail: cong.zhao@utsa.edu..

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Since silver (I) or copper(I) salts are good catalysts for the addition of terminal alkynes to α -iminophosphonates,¹⁰ it is quite reasonable to assume that an enantioselective version of this reaction may be achieved by adding a proper chiral ligand. In the current paper, we wish to report our preliminary results on the first enantioselective synthesis of α -aminopropargylphosphonates through the direct addition of terminal alkynes to an α -iminophosphonate by using a copper(I)-pybox complex as the catalyst. This is the first example where α -iminophosphonate is used as a substrate in the direct enantioselective alkynylation.⁸

By using phenylacetylene (**11a**) and diethyl [(4-methoxyphenyl)imino]methylphosphonate (**12**)¹⁰ as the substrates and Cu(I) triflate toluene complex,¹¹ we first screened several bisoxazoline ligands (Figure 1) for their ability of asymmetric induction. The results are summarized in Table 1.

Although the pybox ligand **1**¹² was reported to be the best one for a similar reaction using α -iminocarboxylate as the substrates,^{8q} it led to a poor enantioselectivity of only 27% of the desired α -aminopropargylphosphonate product (**3a**) in our hand. Nonetheless, the product was obtained in a good yield of 72% (entry 1). Bidentate bisoxazoline ligand **2**¹³ gave even worse enantioselectivities (20% ee, entry 2). Further screening of some C_2 -symmetric 4,4'-disubstituted pybox ligands (**3–7**)^{13,14} revealed that both the sense and the extent of the enantioselectivity of this reaction are dependent on the size of the substituents at the 4 and 4' positions of the oxazoline ring (entries 3–7). With the size of the substituents increases from Me (**3**), to Et (**4**), and then to *i*-Pr (**5**), the enantioselectivity gradually increases from 40% to 53% (entries 3–5). However, further increasing the size to *t*-Bu group (**6**) leads to poorer enantioselectivity (40% ee, entry 6). The opposite enantiomer was obtained as the major product in this case. However, it should be pointed out that ligand **6** has an opposite stereochemistry [(*S,S*)] as compared to ligands **3–5** [(*R,R*)] and, therefore, the sense of stereoselectivity actually remains the same as ligands **3–5**. In contrast, the phenyl-substituted ligand (*R,R*)-**7** leads to an *opposite sense* of stereoselectivity and a poor ee value of the product (22%, entry 7). These results indicate that there are probably two competing orientations of the substrate **12a** when it approaches the metal-ligand complex. Which one of them dominates is dependent on the substituents on the oxazoline rings. Such a phenomenon has been observed previously by Singh and co-workers in the alkynylation of imines with these ligands.⁸ⁿ In order to achieve good enantioselectivity in the reaction, one of these orientations should be avoided, possibly through finely tuning the steric environment of the chiral ligand.⁸ⁿ On the basis of this assumption, (*S,S*) ligands **8–10**^{15,16} were synthesized, with four phenyl groups at the 5 and 5' positions of the oxazoline ring to bias the substrate orientations. Except for ligand **8** (entry 8), which has smaller methyl groups at the 4 and 4' positions, these ligands indeed provide better ee values of the product. For example, ee values of 68% and 74% were obtained for ligand **9** (entry 9) and ligand **10** (entry 10), respectively. Again, the sense of stereoselectivity of these ligands is the same as that of ligands **3–6**.

The effect of copper salts on this reaction was then examined by using the best pybox ligand **10**. The results showed that both Cu(I) triflate benzene complex (entry 11) and Cu(II) triflate (entry 12) produce the same level of enantioselectivity of the product as Cu(I) triflate toluene complex does (entry 10), except that Cu(II) triflate is less reactive: lower yield was obtained at longer reaction time (entry 12). In contrast, Cu(I) hexafluorophosphate acetonitrile complex failed to catalyze the reaction completely (entry 13). Thus, the combination of Cu(I) triflate toluene complex and ligand **10** was identified as the best catalyst in terms of both reactivity and enantioselectivity. The solvent effects on this reaction were also studied. Among the common organic solvents, $CHCl_3$ proved to be the best one for this reaction (entry 10), whereas CH_2Cl_2 (entry 14), toluene (entry 15), and THF (entry 16) all gave either lower yields and/or poorer enantioselectivities. Interestingly, lowering the reaction temperature to 0 °C showed no improvement in the enantioselectivity of this reaction (entry 17). Gratifyingly, it was found

that 10 mol % loading the catalyst is unnecessary, since the reaction with only 2 mol % catalysts gave similar results as those with 10 mol % (entry 18).

Under the optimized reaction conditions (2 mol % of catalyst loading, CHCl_3 as solvent at room temperature) the scope of the reaction was examined with various terminal alkynes.¹⁷ The results are collected in Table 2. Besides phenyl acetylene (entry 1), other aryl-substituted terminal alkynes also participate in this reaction. In the case of mono-substituted phenylacetylenes, the presence of either an electron-donating or withdrawing substituent in the *ortho*, *meta* or *para* positions has almost no influence on the reactivities or the enantioselectivities of the reaction (entries 2–9). The highest enantioselectivity (81% ee) was obtained with the difluorinated phenylacetylene **1j** (entry 10). 1-Ethylenenaphthalene also participates in this reaction, and the desired product (**13k**) was obtained in 72% yield and 60% ee (entry 11). Aliphatic terminal alkynes, such as 1-heptyne and 4-phenyl-1-butyne also afford the expected α -aminopropargylphosphonates in good yields with similar enantioselectivities (64% and 67% ee, respectively; entries 12 and 13).

In summary, we have developed the first enantioselective method for the synthesis of enantioenriched α -aminopropargylphosphonates. In general, high yields and good levels of asymmetric induction (60–81% ee) may be achieved by using Cu(I) triflate and pybox ligand **10**. A low catalyst loading of only 2 mol % is necessary to achieve the desired transformations. The products should be useful for the synthesis of other enantioenriched α -aminophosphonic acid derivatives. The mechanism of this reaction is currently under study and will be disclosed in due time.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors thank the Welch foundation (Grant No. AX-1593) and the NIH-MBRS program (Grant No. S06 GM08194) for the financial support of this research.

References

1. For reviews, see: (a) Kukhar VP, Hudson HR. *Aminophosphonic and Aminophosphinic Acids*. John Wiley & Sons: Chichester, UK; 2000. (b) Kafarski P, Lejczak B. *Curr Med Chem: Anti-Cancer Agents* 2001;1:301–312. (c) Berlicki L, Kafarski P. *Curr Org Chem* 2005;9:1829–1850.
2. (a) Rozenfeld R, Iturriz X, Okada M, Maigret B, Llorens-Cortes C. *Biochemistry* 2003;42:14785–14793. [PubMed: 14674752] (b) Lejczak B, Kafarski P, Zygmunt J. *Biochemistry* 1989;28:3549–3555. [PubMed: 2568128]
3. For a review, see: Kafarski P, Lejczak B. *J Mol Cat B: Enzym* 2004;29:99–104.
4. For reviews, see: (a) Denmark SE, Chatani N, Pansare SV. *Tetrahedron* 1992;48:2191–2208. (b) Uziel J, Genet JP. *Russ J Org Chem* 1997;33:1521–1542. (c) Mikolajczyk M, Lyzwa P, Drabowicz J. *Phosphorus Sulfur Silicon* 1999;144–146:157–160.
5. For examples, see: (a) Gilmore WF, McBride HA. *J Am Chem Soc* 1972;94:4361. [PubMed: 5036657] (b) Zon J. *Pol J Chem* 1981;55:643–646. (c) Kotynski A, Stec WJ. *J Chem Res, Synopsis* 1978:41. (d) Huber JW, Gilmore WP. *Tetrahedron Lett* 1979;20:3049–3052. (e) Kudzin ZH, Stec WJ. *Synthesis* 1978:469–472. (f) Hoppe I, Schollkopf U, Nieger M, Egert E. *Angew Chem, Int Ed Engl* 1985;24:1067–1068. (g) Huber R, Knierzinger A, Obrecht J-P, Vasella A. *Helv Chim Acta* 1985;68:1730–1747. (h) Shatzmiller S, Dolitzky BZ, Meirovich R, Neidlein R, Weik C. *Liebigs Ann Chem* 1991:161–164. (i) Afarinkia K, Rees CW, Cadogan JIG. *Tetrahedron* 1990;46:7175–7196. (j) Yager KM, Taylor CM, Smith AB III. *J Am Chem Soc* 1994;116:9377–9378. (k) Maury C, Gharbaoui T, Royer J, Husson HP. *J Org Chem* 1996;61:3687–3693. [PubMed: 11667216] (l) Yuan C, Li S, Wang G. *Heteroatom Chem* 2000;11:528–535. (m) Yuan C, Li S, Xiao J, Cui S, Wang G. *Phosphorus*

- Sulfur Silicon 2002;177:1731–1734. (n) Davis FA, Wu Y, Yan H, McCoull W, Prasad KR. J Org Chem 2003;68:2410–2419. [PubMed: 12636410] (o) Joly GD, Jacobsen EN. J Am Chem Soc 2004;126:4102–4103. [PubMed: 15053588] (p) Davis FA, Lee SH, Xu H. J Org Chem 2004;69:3774–3781. [PubMed: 15153008] (q) Mikolajczyk M. J Organomet Chem 2005;690:2488–2496. (r) Pettersen D, Marcolini M, Bernardi L, Fini F, Herrera RP, Sgarzani V, Ricci A. J Org Chem 2006;71:6269–6272. [PubMed: 16872218] (s) Akiyama T, Morita H, Itoh J, Fuchibe K. Org Lett 2005;7:2583–2585. [PubMed: 15957896]
6. Schrader T, Kober R, Steglich W. Synthesis 1986:372–375.
7. (a) Kiyohara H, Nakamura Y, Matsubara R, Kobayashi S. Angew Chem Int Ed 2006;45:1615–1617. (b) Kobayashi S, Kiyohara H, Nakamura Y, Matsubara R. J Am Chem Soc 2004;126:6558–6559. [PubMed: 15161276]
8. For examples, see: (a) Fischer C, Carreira EM. Org Lett 2001;3:4319–4321. [PubMed: 11784207] (b) Li CJ, Wei C. Chem Commun 2002:268–269. (c) Wei C, Li CJ. Green Chem 2002;4:39–41. (d) Wei C, Li CJ. J Am Chem Soc 2002;124:5638–5639. [PubMed: 12010027] (e) Wei C, Li CJ. J Am Chem Soc 2003;125:9584–9585. [PubMed: 12904013] (f) Wei C, Li Z, Li CJ. Org Lett 2003;5:4473–4475. [PubMed: 14602028] (g) Fischer C, Carreira EM. Org Lett 2004;6:1497–1499. [PubMed: 15101776] (h) Black DA, Arndtsen BA. Org Lett 2004;6:1107–1110. [PubMed: 15040734] (i) Benaglia M, Negri D, Dell'Anna G. Tetrahedron Lett 2004;45:8705–8708. (j) Wei C, Li Z, Li CJ. Synlett 2004:1472–1483. (k) Wei C, Mague JT, Li C-J. Proc Natl Acad Sci U S A 2004;101:5749–5754. [PubMed: 15067132] (l) Li Z, Wei C, Chen L, Varma RS, Li CJ. Tetrahedron Lett 2004;45:2443–2446. (m) Ju Y, Li CJ, Varma RS. QSAR Comb Sci 2004;23:891–894. (n) Bisai A, Singh VK. Org Lett 2006;8:2405–2408. [PubMed: 16706537] (o) Huang B, Yao X, Li CJ. Adv Syn Cat 2006;348:1528–1532. (p) Ji JX, Au-Yeung TTL, Wu J, Yip CW, Chan ASC. Adv Syn Cat 2004;346:42–44. (q) Ji JX, Wu J, Chan ASC. Proc Natl Acad Sci USA 2005;102:11196–11200. [PubMed: 16061808]
9. (a) Samanta S, Zhao CG. J Am Chem Soc 2006;128:7442–7443. [PubMed: 16756289] (b) Dodda R, Zhao CG. Org Lett 2006;8:4911–4914. [PubMed: 17020334] (c) Mandal T, Samanta S, Zhao CG. Org Lett 2007;9:943–945. [PubMed: 17284048]
10. Dodda R, Zhao CG. Org Lett 2007;9:165–167. [PubMed: 17192111]
11. The more reactive silver(I) triflate always leads to poorer enantioselectivities.
12. Davies IW, Gerena L, Lu N, Larsen RD, Reider PJ. J Org Chem 1996;61:9629–9630.
13. Ligands **2** and **7** were purchased from Aldrich.
14. Ligands **3**–**6** were synthesized according to the following references: a) Provent C, Rivara-Minten E, Hewage S, Brunner G, Williams AF. Chem Eur J 1999;5:3487–3494. b) Nishiyama H, Kondo M, Nakamura T, Itoh K. Organometallics 1991;10:500–508.
15. Ligands **8** and **9** were synthesized according to the following reference: Sekar G, DattaGupta A, Singh VK. J Org Chem 1998;63:2961–2967.
16. The synthesis of ligand **10** was independently reported recently by Singh and co-workers, see: Ginotra SK, Singh VK. Org Biomol Chem 2006;4:4370–4374. [PubMed: 17102883]
17. **General procedure for the synthesis of α -aminopropargylphosphonates:** To an oven-dried 10-mL round-bottom flask was added (CuOTf)₂-toluene complex (0.01 mmol, 2.0 mol %), compound **10** (7.0 mg, 0.011 mmol, 2.1 mol %) and CHCl₃ (3.0 mL). After the mixture was stirred at room temperature for 2 h, a solution of imine **12** (136.0 mg, 0.50 mmol) in CHCl₃ (0.5 mL) was added while vigorous stirring, followed immediately by the terminal alkyne (1.5 mmol). The mixture was further stirred for 10 h at room temperature. After removing the solvent, the crude product was subjected to flash column chromatography (silica gel, 6:4 hexane/EtOAc) for purification, which gives the desired products as pure compounds (for NMR spectroscopic data of the products, see ref. 10).

Figure 1.
Chiral bisoxazolidine ligands screened for the alkynylation of α -iminophosphonate

Table 1

Ligand screening and reaction condition optimizations.^a

Entry	Ligand	CuX	Solvent	Reaction time (h)	Yield (%) ^b	ee (%) ^c
1	1	(CuOTf) ₂ ·toluene	CHCl ₃	10	72	27
2	2	(CuOTf) ₂ ·toluene	CHCl ₃	10	55	20
3	3	(CuOTf) ₂ ·toluene	CHCl ₃	10	81	40
4	4	(CuOTf) ₂ ·toluene	CHCl ₃	10	80	47
5	5	(CuOTf) ₂ ·toluene	CHCl ₃	10	78	53
6	6	(CuOTf) ₂ ·toluene	CHCl ₃	10	73	40 ^e
7	7	(CuOTf) ₂ ·toluene	CHCl ₃	10	88	22 ^e
8	8	(CuOTf) ₂ ·toluene	CHCl ₃	2	93	21 ^e
9	9	(CuOTf) ₂ ·toluene	CHCl ₃	2	90	68 ^e
10	10	(CuOTf) ₂ ·toluene	CHCl ₃	2	91	74 ^e
11	10	(CuOTf) ₂ ·benzene	CHCl ₃	2	80	74 ^e
12	10	Cu(OTf) ₂	CHCl ₃	10	72	74 ^e
13	10	Cu(MeCN) ₄ PF ₆	CHCl ₃	10	—	—
14	10	(CuOTf) ₂ ·toluene	CH ₂ Cl ₂	2	81	74 ^e
15	10	(CuOTf) ₂ ·toluene	toluene	2	45	73 ^e
16	10	(CuOTf) ₂ ·toluene	THF	2	78	65 ^e
17 ^d	10	(CuOTf) ₂ ·toluene	CHCl ₃	10	88	73 ^e
18 ^f	10	(CuOTf) ₂ ·toluene	CHCl₃	10	92	74^e

^a Experimental conditions: Unless otherwise specified, all reactions were conducted with imine **12** (136.0 mg, 0.5 mmol), phenyl acetylene (153 mg, 1.5 mmol), CuX (0.05 mmol, 10 mol %) and the ligand (0.055 mmol, 11 mol %) in anhydrous CHCl₃ (3.0 mL) at room temperature for the specified reaction time.

^b Isolated yields after column chromatography.

^c Enantiomeric excess was determined by chiral HPLC analysis on a Chiralcel OJ-H column; the absolute configuration of the product was not determined.

^d The reaction was carried out at 0 °C.

^e The opposite enantiomer was obtained as the major product.

^f With 2 mol % of (CuOTf)₂·toluene complex and 2.1 mol % of **10**.

Table 2
Enantioselective synthesis of α -aminopropargylphosphonates (13a-m**) from terminal alkynes (**11a-m**) and imine **12**.^a**

Entry	R	Product	Yield (%) ^b	ee (%) ^c
1	Ph	13a	92	74
2	4-BrC ₆ H ₄	13b	88	74
3	2-BrC ₆ H ₄	13c	85	68
4	4-ClC ₆ H ₄	13d	90	74
5	4-FC ₆ H ₄	13e	91	68
6	4-CF ₃ C ₆ H	13f	81	75
7	4-CH ₃ C ₆ H	13g	86	75
8	3-CH ₃ C ₆ H	13h	80	74
9	4-CH ₃ OC ₆ H ₄	13i	88	70
10	3,5-F ₂ C ₆ H	13j	82	81
11	Naph-1-yl	13k	72	60
12 ^d	CH ₃ (CH ₂) ₄	13l	69	64
13 ^d	PhCH ₂ CH	13m	56	67

^a Experimental conditions: unless otherwise indicated, all reactions were conducted with imine **12** (136.0 mg, 0.50 mmol), acetylene (1.5 mmol), (CuOTf)₂-toluene (5.2 mg, 0.010 mmol, 2.0 mol %) and **10** (7.0 mg, 0.011 mmol, 2.1 mol %) in anhydrous CHCl₃ (3.5 mL) at room temperature for 10 h.

^b Yields of isolated products after column chromatography.

^c Enantiomeric excess was determined by chiral HPLC analysis on either a Chiralpak AD-H, or a C hiralcel OJ-H, or a C hiralcel OD-H column; the absolute configurations of the products were not determined

^d The reaction time was 24 h.